JP2022511568A5 - - Google Patents

Info

Publication number
JP2022511568A5
JP2022511568A5 JP2021533154A JP2021533154A JP2022511568A5 JP 2022511568 A5 JP2022511568 A5 JP 2022511568A5 JP 2021533154 A JP2021533154 A JP 2021533154A JP 2021533154 A JP2021533154 A JP 2021533154A JP 2022511568 A5 JP2022511568 A5 JP 2022511568A5
Authority
JP
Japan
Prior art keywords
composition according
smad4
subject
glial
under conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021533154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511568A (ja
JP7518547B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/065742 external-priority patent/WO2020123663A1/en
Publication of JP2022511568A publication Critical patent/JP2022511568A/ja
Publication of JP2022511568A5 publication Critical patent/JP2022511568A5/ja
Priority to JP2024104638A priority Critical patent/JP2024129091A/ja
Application granted granted Critical
Publication of JP7518547B2 publication Critical patent/JP7518547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021533154A 2018-12-11 2019-12-11 統合失調症及び他の神経精神障害の治療方法 Active JP7518547B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024104638A JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778145P 2018-12-11 2018-12-11
US62/778,145 2018-12-11
PCT/US2019/065742 WO2020123663A1 (en) 2018-12-11 2019-12-11 Methods of treating schizophrenia and other neuropsychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024104638A Division JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Publications (3)

Publication Number Publication Date
JP2022511568A JP2022511568A (ja) 2022-01-31
JP2022511568A5 true JP2022511568A5 (enExample) 2022-12-15
JP7518547B2 JP7518547B2 (ja) 2024-07-18

Family

ID=69160318

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021533154A Active JP7518547B2 (ja) 2018-12-11 2019-12-11 統合失調症及び他の神経精神障害の治療方法
JP2024104638A Pending JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024104638A Pending JP2024129091A (ja) 2018-12-11 2024-06-28 統合失調症及び他の神経精神障害の治療方法

Country Status (7)

Country Link
US (1) US20220025379A1 (enExample)
EP (1) EP3894556A1 (enExample)
JP (2) JP7518547B2 (enExample)
CN (2) CN119925614A (enExample)
AU (1) AU2019396450B2 (enExample)
CA (1) CA3122289A1 (enExample)
WO (1) WO2020123663A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110011658A (ko) 2008-05-08 2011-02-08 유니버시티 오브 로체스터 최적화된 세포 제제에 의한 수초 질환의 치료
JP6541577B2 (ja) 2013-02-06 2019-07-10 ユニバーシティー オブ ロチェスター ミエリン障害の治療のための誘導多能性細胞由来オリゴデンドロサイト前駆細胞
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
US11690876B2 (en) 2017-05-10 2023-07-04 University Of Rochester Methods of treating neuropsychiatric disorders
CA3103675A1 (en) 2018-06-21 2019-12-26 University Of Rochester Methods of treating or inhibiting onset of huntington's disease
CN116350758B (zh) * 2023-03-16 2024-08-06 郑州大学 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
ES2234563T5 (es) 1999-02-12 2018-01-17 Daiichi Sankyo Company, Limited Nuevos análogos de nucleósidos y oligonucleótidos
US6013787A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad4 expression
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
DE60310944T3 (de) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Weitere neue formen von interferierende rns moleküle
EP2256201A3 (en) 2003-09-18 2012-07-04 Isis Pharmaceuticals, Inc. Modulation of eIF4E expression
US7128264B2 (en) 2004-07-23 2006-10-31 Symbol Technologies, Inc: Electro-optical reader with improved performance in high intensity ambient light
JP4428296B2 (ja) 2005-06-10 2010-03-10 セイコーエプソン株式会社 表示パネルモジュールおよび表示装置
US9962558B2 (en) * 2005-08-05 2018-05-08 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
US8048999B2 (en) 2005-12-13 2011-11-01 Kyoto University Nuclear reprogramming factor
JP5813321B2 (ja) 2007-03-23 2015-11-17 ウィスコンシン アラムニ リサーチ ファンデーション 体細胞の再プログラム化
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2315829B1 (en) 2008-08-08 2015-02-11 Mayo Foundation For Medical Education And Research Induced pluripotent stem cells
WO2011062963A2 (en) 2009-11-17 2011-05-26 Vitro Diagnositics, Inc. Induced puripotent stem cells and related methods
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
EP2723861A4 (en) * 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
EP3693455A1 (en) * 2011-11-04 2020-08-12 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (da) neurons for engraftment
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
EP3250037A4 (en) 2015-01-16 2018-06-20 The Board of Regents of The University of Texas System Compositions and methods for creating pancreatic cancer animal model

Similar Documents

Publication Publication Date Title
JP2022511568A5 (enExample)
Xu et al. Current knowledge of microglia in traumatic spinal cord injury
JP7406793B2 (ja) ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
EP3394259B1 (en) Compositions and methods for decreasing tau expression
JP2021529169A5 (enExample)
CN111433361B (zh) 天使综合征反义治疗
PE20211749A1 (es) Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos
TWI462741B (zh) 使用微rna 195提供神經保護作用的方法
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
JP2011515357A5 (enExample)
US20190144865A1 (en) Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
JP2009533475A5 (enExample)
US10947538B2 (en) Allele-specific gene suppression
JP2023506842A5 (enExample)
KR20240099216A (ko) 슈반 세포로의 표적화 전달을 위한 설계자 세포외 소낭
CN116376910B (zh) 一种三叉神经痛的标志物及治疗三叉神经的药物
CN103656685B (zh) microRNA-219在制备抗癫痫药物中的应用
JP2015147764A5 (enExample)
JP2024515289A5 (enExample)
MX2022003108A (es) Composicion y metodo para inhibir la acumulacion, agregacion y formacion de ovillos de proteina tau.
JP2021527649A5 (enExample)
RU2839721C2 (ru) Антисмысловые олигонуклеотиды, нацеленные на ген cav3.1, и их применения
US12589133B2 (en) Methods of downregulating CCL20 genes for treatment of traumatic brain injuries
CN106075392B (zh) 促红细胞生成素衍生物在听力保护上的应用
US20220135975A1 (en) Inhibition of let7i as a means to enhance the protective effect of progesterone against stroke